Snigdha Vallabhaneni1, Kaitlin Benedict1, Gordana Derado2, Rajal K Mody1. 1. Mycotic Diseases Branch, Division for Food, Water, and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia. 2. Biostatistics and Information Management Office, Division of Foodborne, Waterborne and Environmental Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
BACKGROUND: Invasive aspergillosis (IA) and mucormycosis contribute to substantial mortality, especially among immunocompromised persons, including those with hematopoietic stem cell transplant (HSCT), hematologic malignancy (HM), and solid organ transplant (SOT). METHODS: Using International Classification of Diseases, Ninth Revision codes available in the National Inpatient Sample, a hospital discharge database, we estimated IA-related hospitalizations (IA-RH), mucormycosis-RH (M-RH), HSCT-RH, HM-RH, and SOT-RH during 2000-2013. United States census data were used to calculate overall M-RH and IA-RH rates and present trends; estimated annual numbers of HSCT-RH, HM-RH, and SOT-RH served as denominators to calculate M-RH and IA-RH rates occurring with these conditions. Weighted least-squares technique was used to test for linear trends and calculate average annual percentage change (APC). RESULTS: There were an estimated 169 110 IA-RH and 9966 M-RH during 2000-2013. Overall, IA-RH and M-RH rates per million persons rose from 32.8 to 46.0 (APC = +2.9; P < .001) and 1.7 to 3.4 (APC = +5.2%; P < .001), respectively, from 2000 to 2013. Among HSCT-RH, there was no significant change in M-RH rate, but a significant decline occurred in IA-RH rate (APC = -4.6%; P = .004). Among HM-RH, the rate of M-RH increased (APC = +7.0%; P < .001), but the IA-RH rate did not change significantly (APC = +1.2%; P = .073). Among SOT-RH, M-RH (APC = +6.3%; P = .038) and IA-RH rates (APC = +4.1%; P < .001) both increased. CONCLUSIONS: Overall IA-RH and M-RH rates increased during 2000-2013, with a doubling of M-RH. Mucormycosis-related hospitalization occurring in conjunction with certain comorbidities increased, whereas IA-RH rates among patients with the comorbidities, decreased, remained stable, or increased to a lesser extent than M-RH. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Invasive aspergillosis (IA) and mucormycosis contribute to substantial mortality, especially among immunocompromised persons, including those with hematopoietic stem cell transplant (HSCT), hematologic malignancy (HM), and solid organ transplant (SOT). METHODS: Using International Classification of Diseases, Ninth Revision codes available in the National Inpatient Sample, a hospital discharge database, we estimated IA-related hospitalizations (IA-RH), mucormycosis-RH (M-RH), HSCT-RH, HM-RH, and SOT-RH during 2000-2013. United States census data were used to calculate overall M-RH and IA-RH rates and present trends; estimated annual numbers of HSCT-RH, HM-RH, and SOT-RH served as denominators to calculate M-RH and IA-RH rates occurring with these conditions. Weighted least-squares technique was used to test for linear trends and calculate average annual percentage change (APC). RESULTS: There were an estimated 169 110 IA-RH and 9966 M-RH during 2000-2013. Overall, IA-RH and M-RH rates per million persons rose from 32.8 to 46.0 (APC = +2.9; P < .001) and 1.7 to 3.4 (APC = +5.2%; P < .001), respectively, from 2000 to 2013. Among HSCT-RH, there was no significant change in M-RH rate, but a significant decline occurred in IA-RH rate (APC = -4.6%; P = .004). Among HM-RH, the rate of M-RH increased (APC = +7.0%; P < .001), but the IA-RH rate did not change significantly (APC = +1.2%; P = .073). Among SOT-RH, M-RH (APC = +6.3%; P = .038) and IA-RH rates (APC = +4.1%; P < .001) both increased. CONCLUSIONS: Overall IA-RH and M-RH rates increased during 2000-2013, with a doubling of M-RH. Mucormycosis-related hospitalization occurring in conjunction with certain comorbidities increased, whereas IA-RH rates among patients with the comorbidities, decreased, remained stable, or increased to a lesser extent than M-RH. Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Maureen M Roden; Theoklis E Zaoutis; Wendy L Buchanan; Tena A Knudsen; Tatyana A Sarkisova; Robert L Schaufele; Michael Sein; Tin Sein; Christine C Chiou; Jaclyn H Chu; Dimitrios P Kontoyiannis; Thomas J Walsh Journal: Clin Infect Dis Date: 2005-07-29 Impact factor: 9.079
Authors: S Husain; D L Paterson; S Studer; J Pilewski; M Crespo; D Zaldonis; K Shutt; D L Pakstis; A Zeevi; B Johnson; E J Kwak; K R McCurry Journal: Am J Transplant Date: 2006-12 Impact factor: 8.086
Authors: S M Trifilio; C L Bennett; P R Yarnold; J M McKoy; J Parada; J Mehta; G Chamilos; F Palella; L Kennedy; K Mullane; M S Tallman; A Evens; M H Scheetz; W Blum; D P Kontoyiannis Journal: Bone Marrow Transplant Date: 2007-02-19 Impact factor: 5.483
Authors: A Minari; R Husni; R K Avery; D L Longworth; M DeCamp; M Bertin; R Schilz; N Smedira; M T Haug; A Mehta; S M Gordon Journal: Transpl Infect Dis Date: 2002-12 Impact factor: 2.228
Authors: Theoklis E Zaoutis; Kateri Heydon; Jaclyn H Chu; Thomas J Walsh; William J Steinbach Journal: Pediatrics Date: 2006-03-13 Impact factor: 7.124
Authors: Greg T Siwek; Kirsty J Dodgson; Margarida de Magalhaes-Silverman; Luther A Bartelt; Sara B Kilborn; Peter L Hoth; Daniel J Diekema; Michael A Pfaller Journal: Clin Infect Dis Date: 2004-07-30 Impact factor: 9.079
Authors: D Neofytos; D Horn; E Anaissie; W Steinbach; A Olyaei; J Fishman; M Pfaller; C Chang; K Webster; K Marr Journal: Clin Infect Dis Date: 2009-02-01 Impact factor: 9.079
Authors: J Sinkó; J Csomor; R Nikolova; S Lueff; G Kriván; P Reményi; A Bátai; T Masszi Journal: Transpl Infect Dis Date: 2007-07-01 Impact factor: 2.228
Authors: Jeremy A W Gold; Andrew Revis; Stepy Thomas; Lewis Perry; Rebekah A Blakney; Taylor Chambers; Meghan L Bentz; Elizabeth L Berkow; Shawn R Lockhart; Colleen Lysen; Natalie S Nunnally; Alexander Jordan; Hilary C Kelly; Alejandro J Montero; Monica M Farley; Nora T Oliver; Stephanie M Pouch; Andrew S Webster; Brendan R Jackson; Karlyn D Beer Journal: Open Forum Infect Dis Date: 2022-04-21 Impact factor: 4.423
Authors: Ashley V Nywening; Jeffrey M Rybak; Phillip David Rogers; Jarrod R Fortwendel Journal: Environ Microbiol Date: 2020-10-21 Impact factor: 5.491
Authors: Marya D Zilberberg; Brian H Nathanson; Rachel Harrington; James R Spalding; Andrew F Shorr Journal: Clin Infect Dis Date: 2018-08-16 Impact factor: 9.079
Authors: Shobini Sivagnanam; Dhruba J Sengupta; Daniel Hoogestraat; Rupali Jain; Zach Stednick; David N Fredricks; Paul Hendrie; Estella Whimbey; Sara T Podczervinski; Elizabeth M Krantz; Jeffrey S Duchin; Steven A Pergam Journal: Antimicrob Resist Infect Control Date: 2017-12-06 Impact factor: 4.887
Authors: Anita H Sung; Stephan Martin; Bryant Phan; Michael Benigno; Jennifer Stephens; Richard Chambers; Jalal A Aram Journal: Clinicoecon Outcomes Res Date: 2021-06-25